Evommune (NYSE:EVMN) Director Sells $123,118.48 in Stock

Evommune, Inc. (NYSE:EVMN) Director David Cohen sold 6,056 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $20.33, for a total transaction of $123,118.48. Following the completion of the transaction, the director directly owned 17,609 shares of the company’s stock, valued at $357,990.97. This trade represents a 25.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Evommune Price Performance

NYSE:EVMN opened at $19.87 on Friday. The firm has a market capitalization of $715.68 million and a price-to-earnings ratio of -2.09. The business has a 50-day simple moving average of $23.91. Evommune, Inc. has a 12-month low of $13.89 and a 12-month high of $33.20.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.19. Equities research analysts expect that Evommune, Inc. will post -2.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on EVMN. Oppenheimer began coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target for the company. Evercore reissued an “outperform” rating and set a $55.00 price target on shares of Evommune in a research report on Tuesday, February 10th. Royal Bank Of Canada restated an “outperform” rating and set a $48.00 price objective on shares of Evommune in a report on Friday, April 10th. Stifel Nicolaus began coverage on shares of Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Evommune in a research note on Tuesday, May 26th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $49.25.

Institutional Trading of Evommune

Several hedge funds and other institutional investors have recently modified their holdings of the stock. EQT Fund Management S.a r.l. bought a new stake in shares of Evommune during the 4th quarter worth about $84,395,000. RA Capital Management L.P. bought a new stake in Evommune in the 4th quarter valued at about $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC bought a new stake in shares of Evommune during the 4th quarter worth approximately $32,989,000. Nan Fung Group Holdings Ltd bought a new stake in shares of Evommune during the 4th quarter worth approximately $24,670,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Evommune during the 4th quarter worth approximately $22,408,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.